NASDAQ:SURF Surface Oncology (SURF) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.0950-Day Range$0.88▼$1.0852-Week Range$0.56▼$1.43Volume1.51 million shsAverage Volume430,375 shsMarket Capitalization$65.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Surface Oncology alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Surface Oncology Stock (NASDAQ:SURF)Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.Read More Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! SURF Stock News HeadlinesJuly 26 at 12:36 AM | msn.comDoctor's honest answer over belief people can get cancer because of 'bad luck'July 25 at 7:35 PM | msn.comSimple blood test may predict CAR-T therapy success in multiple myelomaJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 24 at 5:25 PM | finance.yahoo.comSustainability in milling: A greener future for 2024?July 24 at 5:25 PM | msn.comBlood test may guide use of multiple myeloma immunotherapyJuly 24 at 5:25 PM | msn.comClinical trial shows improved survival with blinatumomab in B-cell precursor leukemia subtypeJuly 22, 2024 | msn.comKnockout of CD5 on CAR T cells shown to boost anti-tumor efficacyJuly 20, 2024 | bizjournals.comPioneering dermatologist Dr. Anthony Benedetto sells practice to fast-growing physician groupJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 20, 2024 | msn.comVHIO-led study shows the preclinical promise of systemic targeted therapy in pseudomyxoma peritoneiMay 29, 2024 | msn.comHow the Moves of One Company Are Revolutionizing the Healthcare SectorMay 29, 2024 | finance.yahoo.comCDR-Life Announces Initiation of CDR404 Phase 1 Trial for Treatment of Solid Tumors at ASCOMay 28, 2024 | msn.comTattoos linked to higher risk of malignant lymphoma, study findsMay 28, 2024 | msn.comCan the placement of dental implants in head and neck cancer patients be done before radiation therapy?May 27, 2024 | msn.comCork's CUH is first Irish hospital to offer breakthrough liver cancer therapyMay 25, 2024 | msn.comEvolving treatment paradigms in multiple myeloma could improve patient outcomesMay 24, 2024 | msn.comHPV vaccines can prevent cancer in men as well as women: StudyMay 24, 2024 | msn.comQ&A: Quadruple therapies and the future of multiple myeloma treatmentSee More Headlines Receive SURF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SURF CUSIPN/A CIK1718108 Webwww.surfaceoncology.com Phone(617) 714-4096FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,590,000.00 Net MarginsN/A Pretax Margin-211.95% Return on Equity-107.81% Return on Assets-65.57% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$30 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.32Miscellaneous Outstanding Shares60,824,000Free Float53,525,000Market Cap$65.08 million OptionableNot Optionable Beta1.75 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Lisa McGrathChief People OfficerMs. Shannon Rourke DevensSr. VP of Devel. OperationsKey CompetitorsLianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXMPolarityTENASDAQ:PTEIQ9 Meters BiopharmaNASDAQ:NMTRKaleido BiosciencesNASDAQ:KLDOView All CompetitorsInsidersJessica FeesSold 9,434 sharesTotal: $8,867.96 ($0.94/share)Robert W RossSold 16,713 sharesTotal: $15,710.22 ($0.94/share)Chandra AdamsSold 3,901 sharesTotal: $3,666.94 ($0.94/share) SURF Stock Analysis - Frequently Asked Questions How were Surface Oncology's earnings last quarter? Surface Oncology, Inc. (NASDAQ:SURF) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.04. The business earned $0.39 million during the quarter. What is Jeff Goater's approval rating as Surface Oncology's CEO? 5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Surface Oncology IPO? Surface Oncology (SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO. What other stocks do shareholders of Surface Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO) and NVIDIA (NVDA). This page (NASDAQ:SURF) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surface Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surface Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
